6-chloro-2-(6-chloro-pyridin-3-ylmethyl)-2H-pyridazin-3-ylideneamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-chloro-2-(6-chloro-pyridin-3-ylmethyl)-2H-pyridazin-3-ylideneamine
• 英文别名: 6-Chloro-2-[(6-chloropyridin-3-yl)methyl]pyridazin-3-imine
• 化学式: C₁₀H₈Cl₂N₄
• 分子量: 255.106
• InChiKey: UKENXGFVMMBWDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome
  申请人：Pfizer Inc.

  公开号：US20030134844A1

  公开（公告）日：2003-07-17

  This invention relates to the use of nicotinic acetylcholine receptor agonists for the treatment of restless legs syndrome (RLS). The invention further relates to the use of a nicotinic acetylcholine receptor agonist in the manufacture of a medicament for the treatment of RLS. The present invention also relates to a pharmaceutical composition for the treatment of RLS containing a nicotinic acetylcholine receptor agonist.

  这项发明涉及尼古丁型乙酰胆碱受体激动剂用于治疗不安腿综合征（RLS）。该发明还涉及尼古丁型乙酰胆碱受体激动剂在制造治疗RLS药物中的应用。本发明还涉及一种含有尼古丁型乙酰胆碱受体激动剂的治疗RLS的药物组合物。
• Heterocyclic compounds having effect of activating a4beta2 nicotinic acetylcholine receptors
  申请人：SUNTORY LIMITED

  公开号：US20020028809A1

  公开（公告）日：2002-03-07

  There is provided heterocyclic compounds of the following formula (I): 1 in which, A is optionally substituted aryl group or optionally substituted heterocyclic group; X is oxygen atom, sulfur atom, carbon atom or nitrogen atom; dotted line shows either presence or absence of bond; n is integer of 1 or 2; and Y represents alkylene bond and so on; or a pharmaceutically acceptable salt thereof. These compounds have good affinity to &agr;4&bgr;2 nicotinic acetylcholine receptors and activate the same to thereby exert a preventive or therapeutic effect on cerebral dysfunction.

  提供了以下式子（I）的杂环化合物：1其中，A是可选择取代的芳基或可选择取代的杂环基；X是氧原子、硫原子、碳原子或氮原子；虚线表示键的存在或不存在；n是1或2的整数；Y表示烷基键等；或其药学上可接受的盐。这些化合物与α4β2型尼古丁乙酰胆碱受体具有良好的亲和力，并激活它们，从而对脑功能障碍产生预防或治疗作用。
• HETEROCYCLIC COMPOUNDS HAVING EFFECT OF ACTIVATING NICOTINIC ACETYLCHOLINE $g(a)4$g(b)2 RECEPTOR
  申请人：SUNTORY LIMITED

  公开号：EP1176141A1

  公开（公告）日：2002-01-30

  There is provided heterocyclic compounds of the following formula (I):    in which, A is optionally substituted aryl group or optionally substituted heterocyclic group; X is oxygen atom, sulfur atom, carbon atom or nitrogen atom; dotted line shows either presence or absence of bond; n is integer of 1 or 2; and Y represents alkylene bond and so on; or a pharmaceutically acceptable salt thereof. These compounds have good affinity to α4β2 nicotinic acetylcholine receptors and activate the same to thereby exert a preventive or therapeutic effect on cerebral dysfunction.

  提供了下式(I)的杂环化合物：其中，A为任选取代的芳基或任选取代的杂环基团；X为氧原子、硫原子、碳原子或氮原子；虚线表示存在或不存在键；n为1或2的整数；Y代表烯键等，或其药学上可接受的盐。 这些化合物对α4β2烟碱乙酰胆碱受体具有良好的亲和力，并能激活该受体，从而对脑功能障碍起到预防或治疗作用。
• Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome
  申请人：Saltarelli D. Mario

  公开号：US20050250806A1

  公开（公告）日：2005-11-10

  This invention relates to the use of nicotinic acetylcholine receptor agonists for the treatment of restless legs syndrome (RLS). The invention further relates to the use of a nicotinic acetylcholine receptor agonist in the manufacture of a medicament for the treatment of RLS. The present invention also relates to a pharmaceutical composition for the treatment of RLS containing a nicotinic acetylcholine receptor agonist.

  本发明涉及使用烟碱乙酰胆碱受体激动剂治疗不宁腿综合征（RLS）。本发明还涉及使用烟碱乙酰胆碱受体激动剂制造治疗 RLS 的药物。本发明还涉及一种含有烟碱乙酰胆碱受体激动剂的治疗 RLS 的药物组合物。
• (N-(pyridinylmethyl)-heterocyclic)-ylideneamine compounds as nicotinic acetylcholine receptor binding agents
  申请人：PFIZER INC.

  公开号：EP0857725B1

  公开（公告）日：2001-07-25